Basic Searches
Searches without any special characters (listed below) will return items that contain the exact value(s) entered in the search field. This means that searching for "ASPIRIN CALCIUM" won't return any items that have "ASPIRIN GLYCINE CALCIUM" because the search term doesn't match exactly.
Boolean Operators
OR - searches with terms separated by " OR " will return items that contain any of the terms in the search.
Example: "ASPIRIN" OR "CALCIUM" will return items that have strings like "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because they contain at least one of the terms in the search.

AND - searches with terms separated by " AND " will return items that contain all the terms in the search.
Example: "ASPIRIN" AND "CALCIUM" won't return items that have strings "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because neither contain both terms, but it will return "ASPIRIN GLYCINE CALCIUM" because it contains both search terms.
version 2.7.1
Substance Class Protein
Protein Sub Type
Sequence Type COMPLETE
Record UNII
NQI5D806LC
Record Status Validated
Record Version
Show Definitional References Hide Definitional References
Download
Name Type Language Details Access References
5-HYDROXYTRYPTAMINE RECEPTOR 2A
Common Name
English  
SEROTONIN RECEPTOR 2A
Common Name
English  
HTR2
Common Name
English  
5-HT2A RECEPTOR
Common Name
English  
5-HT2A
Common Name
English  
5-HT-2
Common Name
English  
Code System Code Type Description Access References
FDA UNII
NQI5D806LC
Created by admin on Wed Aug 04 22:04:52 EDT 2021 , Edited by admin on Wed Aug 04 22:04:52 EDT 2021
PRIMARY
PHAROS
P28223
Created by admin on Wed Aug 04 22:04:52 EDT 2021 , Edited by admin on Wed Aug 04 22:04:52 EDT 2021
PRIMARY
UNIPROT
P28223
Created by admin on Wed Aug 04 22:04:52 EDT 2021 , Edited by admin on Wed Aug 04 22:04:52 EDT 2021
PRIMARY
From To
1_148 1_227
1_349 1_353
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_8
N 1_38
N 1_44
N 1_51
N 1_54
Related Record Type Details Access References
INVERSE AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:53 EDT 2021 , Edited by admin on Wed Aug 04 22:04:53 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:53 EDT 2021 , Edited by admin on Wed Aug 04 22:04:53 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
INHIBITOR
Ki
Created by admin on Wed Aug 04 22:04:53 EDT 2021 , Edited by admin on Wed Aug 04 22:04:53 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
MAJOR
Ki
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
RADIOLIGAND->TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
RADIOLIGAND->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:53 EDT 2021 , Edited by admin on Wed Aug 04 22:04:53 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
all of the tryptamines, including DMT but with the exception of psilocin, were more potent agonists at the 5-HT2A receptor than LSD in the assay that was used in the present study. LSD and psilocin were 5-HT2A receptor partial agonists, with 28% and 16% activation efficacy, respectively, whereas all of the other compounds presented higher 5-HT2A receptor activation efficacies (up to >80% for DiPT and 5-MeO-MiPT).
EC50
Created by admin on Wed Aug 04 22:04:53 EDT 2021 , Edited by admin on Wed Aug 04 22:04:53 EDT 2021
INVERSE AGONIST->TARGET
Mediator Substance Details
none
AGONIST
Ki
Created by admin on Wed Aug 04 22:04:56 EDT 2021 , Edited by admin on Wed Aug 04 22:04:56 EDT 2021
ANTAGONIST->TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:53 EDT 2021 , Edited by admin on Wed Aug 04 22:04:53 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
RADIOLIGAND->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:53 EDT 2021 , Edited by admin on Wed Aug 04 22:04:53 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:52 EDT 2021 , Edited by admin on Wed Aug 04 22:04:52 EDT 2021
PARTIAL AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
RADIOLIGAND->TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
PARTIAL AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
PARTIAL AGONIST->TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
WEAK INHIBITOR->TARGET
none
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:56 EDT 2021 , Edited by admin on Wed Aug 04 22:04:56 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
INHIBITOR
Ki
Created by admin on Wed Aug 04 22:04:53 EDT 2021 , Edited by admin on Wed Aug 04 22:04:53 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:56 EDT 2021 , Edited by admin on Wed Aug 04 22:04:56 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:52 EDT 2021 , Edited by admin on Wed Aug 04 22:04:52 EDT 2021
RADIOLIGAND->TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:56 EDT 2021 , Edited by admin on Wed Aug 04 22:04:56 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:53 EDT 2021 , Edited by admin on Wed Aug 04 22:04:53 EDT 2021
ANTAGONIST->TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:56 EDT 2021 , Edited by admin on Wed Aug 04 22:04:56 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:56 EDT 2021 , Edited by admin on Wed Aug 04 22:04:56 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
PARTIAL AGONIST->TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:53 EDT 2021 , Edited by admin on Wed Aug 04 22:04:53 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
BINDING
cell:CHO; ligand: 3-H-KETASERIN
Ki
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:52 EDT 2021 , Edited by admin on Wed Aug 04 22:04:52 EDT 2021
PARTIAL AGONIST->TARGET
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:56 EDT 2021 , Edited by admin on Wed Aug 04 22:04:56 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
RADIOLIGAND->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 22:04:55 EDT 2021 , Edited by admin on Wed Aug 04 22:04:55 EDT 2021
Structural Modifications
Modification Type Location Site Location Type Residue Modified Extent Modification Name Modification ID Access
AMINO ACID SUBSTITUTION [1_280] DEXFOSFOSERINE VI4F0K069V
Name Property Type Amount Referenced Substance Defining Parameters Access References
MOL_WEIGHT CHEMICAL
0
Created Wed Aug 04 22:04:44 EDT 2021
Created By admin
Last Edited Wed Aug 04 22:04:44 EDT 2021
Last Edited By admin
Index Source Text / Citation Source Type Tags Date Accessed File Access
1 https://www.drugbank.ca/drugs/DB00924 WEB PAGE
2 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
3 WIKI WIKI PUBLIC_DOMAIN_RELEASE
4 https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
5 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
6 Corena-McLeod, Maria. "Comparative pharmacology of risperidone and paliperidone." Drugs in R&D 15.2 (2015): 163-174. JA
7 SRS import [NQI5D806LC] SRS NOMEN Fri Apr 28 15:31:15 EDT 2017
8 https://www.jpain.org/article/S1526-5900(11)00268-9/abstract MEETING ABSTRACT
9 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
10 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
11 https://www.drugbank.ca/drugs/DB00370 WEB PAGE
12 https://www.drugbank.ca/drugs/DB08810 WEB PAGE
13 https://www.drugbank.ca/drugs/DB01151 WEB PAGE
14 Monostory, Katalin, et al. "Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human." Drug metabolism and disposition 33.11 (2005): 1708-1716. JA PUBLIC_DOMAIN_RELEASE
15 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
16 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
17 FDA_SRS SRS NOMEN PUBLIC_DOMAIN_RELEASE AUTO_SELECTED
18 https://www.drugbank.ca/drugs/DB09016 WEB PAGE
19 https://www.drugbank.ca/drugs/DB00805 WEB PAGE
20 Doggrell, Sheila A. "Sarpogrelate: cardiovascular and renal clinical potential." Expert opinion on investigational drugs 13.7 (2004): 865-874. JA
21 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209500Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
22 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
23 STN STN (SCIFINDER)
24 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209500Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
25 https://www.drugbank.ca/drugs/DB00408 WEB PAGE
26 Megens, A. A., et al. "Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598)." Journal of Pharmacology and Experimental Therapeutics 260.1 (1992): 146-159. JA
27 https://www.drugbank.ca/drugs/DB01238 WEB PAGE
28 Farré M, Roset PN, Llorente M, et al. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration. Methods and Findings in Experimental and Clinical Pharmacology. 199Farré M, Roset PN, Llorente M, et al. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration. Methods and Findings in Experimental and Clinical Pharmacology. 1997 Jun;19(5):343-350.7 Jun;19(5):343-350. JA PUBLIC_DOMAIN_RELEASE
29 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
30 WO 2018213813 A2 PATENT
31 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
32 WIKIPEDIA WIKIPEDIA NOMEN PUBLIC_DOMAIN_RELEASE
33 Rickli, Anna, et al. "Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens." European Neuropsychopharmacology 26.8 (2016): 1327-1337. JA
34 https://www.drugbank.ca/drugs/DB00875 WEB PAGE
35 https://www.xocpharma.com/file.cfm/7/docs/AHS_2019_Poster_2_XocPharma_Final.pdf COMPANY WEB PAGE NOMEN PUBLIC_DOMAIN_RELEASE POT
36 https://www.drugbank.ca/drugs/DB01242 WEB PAGE
37 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
38 DeLarge, Alyssa F., Laura L. Erwin, and Peter J. Winsauer. "Atypical binding at dopamine and serotonin transporters contribute to the discriminative stimulus effects of mephedrone." Neuropharmacology 119 (2017): 62-75. JA
39 Front. Pharmacol., 31 March 2016, Declercq, LD, et.al. JA PUBLIC_DOMAIN_RELEASE
40 https://www.drugbank.ca/drugs/DB00604 WEB PAGE
41 http://www.uniprot.org/uniprot/P28223 SRS NOMEN PUBLIC_DOMAIN_RELEASE AUTO_SELECTED
42 https://www.drugbank.ca/drugs/DB00434 WEB PAGE
43 https://www.pharmaceutical-networking.com/eli-lilly-ly2624803-treatment-of-chronic-insomnia/ SRS NOMEN
44 Rickli, Anna, et al. "Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens." European Neuropsychopharmacology 26.8 (2016): 1327-1337. JA
45 SRS CODE IMPORT SRS NOMEN Fri Apr 28 15:31:15 EDT 2017
46 WO 2018213813 A2 PATENT
47 https://www.drugbank.ca/drugs/DB00247 WEB PAGE
48 https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
49 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
50 https://www.pharmaceutical-networking.com/eli-lilly-ly2624803-treatment-of-chronic-insomnia/ WEBSITE NOMEN
51 Generated from relationship on:'PIMAVANSERIN' SYSTEM
52 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
53 Front. Pharmacol., 31 March 2016, Declercq, LD, et.al. JA PUBLIC_DOMAIN_RELEASE
54 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
55 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
56 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
57 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
58 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
59 https://www.drugbank.ca/drugs/DB00696 WEB PAGE
60 Corena-McLeod, Maria. "Comparative pharmacology of risperidone and paliperidone." Drugs in R&D 15.2 (2015): 163-174. JA
61 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
62 WIKIPEDIA WIKI PUBLIC_DOMAIN_RELEASE
63 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
64 http://www.uniprot.org/uniprot/P28223?sort=score SRS NOMEN
65 https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022117s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
66 https://www.drugbank.ca/drugs/DB00363 WEB PAGE
67 WIKI WIKI PUBLIC_DOMAIN_RELEASE
68 https://www.drugbank.ca/drugs/DB00321 WEB PAGE
69 Dannals, Robert F., et al. "Synthesis of a radiotracer for studying serotonin-2 receptors: carbon-11 labeled N-methylketanserin." J Label Compds Radiopharm 26, pt.1-12 (1989): 195-196. MEETING ABSTRACT NOMEN PUBLIC_DOMAIN_RELEASE SYNTH
70 https://www.drugbank.ca/drugs/DB01239 WEB PAGE
71 https://www.drugbank.ca/drugs/DB09128 WEB PAGE
72 https://www.drugbank.ca/drugs/DB01614 WEB PAGE
73 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
74 nflis-LIST SRS NOMEN PUBLIC_DOMAIN_RELEASE
75 https://www.drugbank.ca/drugs/DB00933 WEB PAGE
76 https://www.drugbank.ca/drugs/DB01142 WEB PAGE
77 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
78 Generated from relationship on:'LY-2624803' SYSTEM
79 https://www.drugbank.ca/drugs/DB01442 WEB PAGE
80 WIKI WIKI PUBLIC_DOMAIN_RELEASE
81 ITI 333 WEB PAGE
82 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
83 UNIPROT UNIPROT NOMEN
84 WIKIPEDIA WIKI NOMEN PUBLIC_DOMAIN_RELEASE
85 https://www.drugbank.ca/drugs/DB00477 WEB PAGE
86 https://www.drugbank.ca/drugs/DB00589 WEB PAGE
87 dump-public-2021-07-22_UPDATED.gsrs BATCH_IMPORT Wed Aug 04 22:04:35 EDT 2021
88 https://www.drugbank.ca/drugs/DB04908 WEB PAGE
89 da Cunha-Bang, Sofi, et al. "Measuring endogenous changes in serotonergic neurotransmission with [11 C] Cimbi-36 positron emission tomography in humans." Translational psychiatry 9.1 (2019): 1-10. JA
90 https://www.drugbank.ca/drugs/DB06016 WEB PAGE
91 https://www.drugbank.ca/drugs/DB08815 WEB PAGE
92 Simen, Arthur A., et al. "Efavirenz modulation of sleep spindles and sleep spectral profile." Journal of sleep research 24.1 (2015): 66-73. JA
93 WIKIPEDIA WIKI NOMEN PUBLIC_DOMAIN_RELEASE